{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=35", "query": { "intervention": "docetaxel", "page": 35 }, "page_size": 10 }, "pagination": { "page": 35, "page_size": 10, "total_count": 1321, "total_pages": 133, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=36&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=34&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T12:51:21.556Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03598595", "title": "Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Osteosarcoma", "Refractory Osteosarcoma" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 31, "start_date": "2019-01-28", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-10-29T12:51:21.556Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03598595" }, { "nct_id": "NCT03976375", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 422, "start_date": "2019-06-26", "completion_date": "2024-08-22", "has_results": true, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-10-29T12:51:21.556Z", "location_count": 28, "location_summary": "Bakersfield, California • Fleming Island, Florida • Orange City, Florida + 24 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Fleming Island", "state": "Florida" }, { "city": "Orange City", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03976375" }, { "nct_id": "NCT03487601", "title": "Transcranial Direct Current Stimulation (tDCS) to Improve Fatigue and Cognitive Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Fatigue" ], "interventions": [ { "name": "transcranial direct current stimulation", "type": "OTHER" }, { "name": "sham transcranial direct current stimulation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-12-12", "completion_date": "2019-02-16", "has_results": false, "last_update_posted_date": "2021-01-15", "last_synced_at": "2026-10-29T12:51:21.556Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03487601" }, { "nct_id": "NCT06241456", "title": "FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "FT825", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 351, "start_date": "2024-01-05", "completion_date": "2044-05-01", "has_results": false, "last_update_posted_date": "2025-12-09", "last_synced_at": "2026-10-29T12:51:21.556Z", "location_count": 14, "location_summary": "Gilbert, Arizona • La Jolla, California • New Haven, Connecticut + 11 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06241456" }, { "nct_id": "NCT04666129", "title": "Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer", "Metastatic Castration-Sensitive Prostate Cancer", "Non-Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 48, "start_date": "2021-02-18", "completion_date": "2024-05-28", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-10-29T12:51:21.556Z", "location_count": 16, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Lakewood", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04666129" }, { "nct_id": "NCT00193245", "title": "Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Topotecan", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2000-11", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2010-06-28", "last_synced_at": "2026-10-29T12:51:21.556Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00193245" }, { "nct_id": "NCT04154956", "title": "SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer Metastatic" ], "interventions": [ { "name": "SAR408701", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 389, "start_date": "2020-02-06", "completion_date": "2026-04-16", "has_results": true, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-10-29T12:51:21.556Z", "location_count": 8, "location_summary": "Fort Myers, Florida • St. Petersburg, Florida • Grand Rapids, Michigan + 5 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "Wynnewood", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04154956" }, { "nct_id": "NCT00118131", "title": "Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 49, "start_date": "2003-12", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2023-08-15", "last_synced_at": "2026-10-29T12:51:21.556Z", "location_count": 13, "location_summary": "East Brunswick, New Jersey • Edison, New Jersey • Freehold, New Jersey + 9 more", "locations": [ { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Edison", "state": "New Jersey" }, { "city": "Freehold", "state": "New Jersey" }, { "city": "Hamilton", "state": "New Jersey" }, { "city": "Long Branch", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118131" }, { "nct_id": "NCT05408845", "title": "Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Salivary Gland Carcinoma", "Recurrent Salivary Gland Carcinoma", "Stage III Major Salivary Gland Cancer AJCC v8", "Stage IV Major Salivary Gland Cancer AJCC v8", "Unresectable Salivary Gland Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "2023-03-03", "completion_date": "2033-07-31", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-29T12:51:21.556Z", "location_count": 154, "location_summary": "Birmingham, Alabama • Duarte, California • Dublin, California + 127 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Dublin", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05408845" }, { "nct_id": "NCT02331251", "title": "Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Breast Cancer", "Sarcoma", "Pancreatic Cancer", "Small Cell Lung Cancer", "Ovarian" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Liposomal Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Western Regional Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2014-12", "completion_date": "2018-01", "has_results": false, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-10-29T12:51:21.556Z", "location_count": 2, "location_summary": "Goodyear, Arizona", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02331251" } ] }